Philippe Grand

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.